Mirum Pharmaceuticals (MIRM) is back in focus after the company highlighted four upcoming pivotal clinical study readouts over the next 18 months, along with new inducement equity awards granted to 12 new employees.

Recent trading reflects mixed momentum, with a 4.1% 1 month share price return and a 23.5% year to date share price return. The 1 year total shareholder return of about 1.5x suggests strong longer term gains as attention builds around upcoming trial readouts and recent hiring related equity grants.

If Mirum’s rare disease pipeline has caught your eye, this is a good moment to see what else is moving in the space and scan 35 healthcare AI stocks

With Mirum shares up 23.5% year to date and trading at about a 30% discount to the average analyst price target, plus an implied intrinsic discount near 73%, you now have to ask: is this a genuine opportunity, or are markets already pricing in future growth?

Most Popular Narrative: 9.6% Undervalued

Mirum's most followed narrative pegs fair value at about $106.60 per share versus the last close of $96.40, putting a modest valuation gap in focus for investors weighing those upcoming trial readouts.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

Curious what sits behind that fair value upgrade? The narrative leans on faster revenue expansion, rising margins, and a rich future earnings multiple that assumes meaningful execution on the late stage pipeline.

Result: Fair Value of $106.60 (UNDERVALUED)

However, that 9.6% gap to fair value leans heavily on Livmarli holding its commercial footing, as well as on upcoming PSC and other late stage data landing as expected.

Next Steps

With sentiment split between opportunity and caution, it makes sense to look at the data yourself and not just the headlines. To see how the current upside story compares with the concerns already flagged, take a closer look at the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

While Mirum may be on your radar, you might not want to stop at a single name when there are other targeted ideas worth checking through the screener.

• Target resilient income by scanning companies that offer reliable payouts in the 11 dividend fortresses.
• Hunt for potential mispricing by checking out the 60 high quality undervalued stocks before the crowd closes the gap.
• Prioritise capital protection first and look through the 72 resilient stocks with low risk scores so you are not taking on more risk than you intend.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.